Castle Biosciences to Participate in Upcoming Investor Conferences

FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m. Eastern time.

A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at https://ir.castlebiosciences.com/news-events/ir-events. A replay of the webcast will be available following the conclusion of the live broadcast.

Castle will also be available for one-on-one investor meetings during the 10^th annual Lake Street Best Ideas Growth (BIG10) Conference on Thursday, Sept. 10, 2026. Meetings may be requested exclusively through Lake Street Capital Markets.

About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X. 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact:
Camilla Zuckero
[email protected] 

Media Contact:
Allison Marshall
[email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/castle-biosciences-to-participate-in-upcoming-investor-conferences-302855676.html

SOURCE Castle Biosciences, Inc.